New hope for the most vulnerable: slower treatment could help frailest cancer patients

NCT ID NCT06517017

Summary

This study is testing a gentler, slower approach to starting treatment for very frail patients with multiple myeloma, a type of blood cancer. Researchers want to see if starting with two drugs and slowly adding a third helps patients stick with treatment longer and feel better. The goal is to find a more tolerable treatment plan for this vulnerable group, who often struggle with standard, more intense therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute at the University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.